Skip header and navigation

6 records – page 1 of 1.

Document Type
Rapid Review
Review Code
EOC210901 RR
Question Submitted
September 21, 2021
Date Completed
September 30, 2021
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC210901 RR
Question Submitted
September 21, 2021
Date Completed
September 30, 2021
Status
3. Completed
Research Team
EOC
Key Findings
September 30, 2021
Studies conducted before mass vaccination campaigns began have reported proper and consistent facemasking by students and staff in school settings are associated with reduced incidence of school-associated transmission or seropositivity.
Fewer studies have reported efficacy of facemasking in the post-mass vaccination period in school settings. The studies available report, however, school-associated transmission were lower, less than 1% secondary attack rate in schools.
Studies of school-associated COVID-19 cases find community exposure to SARS-CoV-2 and/or noncompliance with multiple mitigation measures (e.g. facemask policies, distancing, non-isolation, etc) are key factors of clusters and outbreaks in children.
Category
Infection Prevention and Control
Subject
Face Masks
Public Health
Schools
Pediatrics
Population
All Pediatrics
All adults
Clinical Setting
Public Health
Priority Level
Level 4 Three weeks (21 days)
Cite As
Badea, A; Groot, G; Muhajarine, N; Howell-Spooner, B; Young, C. What is the evidence for the effectiveness of universal mask use in the pediatric population? 2021 Sep 30, Document no.: EOC210901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC210901 ESR
Question Submitted
September 21, 2021
Date Completed
September 28, 2021
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC210901 ESR
Question Submitted
September 21, 2021
Date Completed
September 28, 2021
Status
3. Completed
Research Team
EOC
Category
Infection Prevention and Control
Subject
Face Masks
Pediatrics
Schools
Public Health
Population
All Pediatrics
All adults
Clinical Setting
Public Health
Priority Level
Level 4 Three weeks (21 days)
Cite As
Howell-Spooner, B., Young, C.. What is the evidence for the effectiveness of universal mask use in the pediatric population?? 2021 Sep 28, Document no.: EOC210901 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 25 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC070201v2 RR
Question Submitted
July 2, 2020
Date Completed
August 14, 2020
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC070201v2 RR
Question Submitted
July 2, 2020
Date Completed
August 14, 2020
Status
5. Updated review
Research Team
EOC
Updated Key Findings
AUGUST 7th UPDATE: No new studies examining secondary attack rates of pediatric index cases were found. Studies continue to suggest low transmission from pediatric cases, and high proportion of pediatric cases being asymptomatic to mildly symptomatic.
Key Findings
· Pediatric cases of COVID-19 constitute between 1% to 10% of all confirmed cases of COVID-19; variation exists by jurisdiction. · Few case reports exist of confirmed child-to-other transmission. Contact tracing studies suggest that children are unlikely to be transmitters of the disease. Households are the most likely environments for transmission. · A recent large South Korean contact tracing study however (in pre-print) found that household COVID-19 transmission rates for children age 10-19 were significantly higher than in adults; transmission rates for children age 0-9 were relatively low.
Category
Infection Prevention and Control
Epidemiology
Subject
Pediatrics
Transmission
Symptoms
Natural History
Priority Level
Level 5 completed within 2 weeks
Cite As
Sulaiman, F; Groot, G; Muhajarine, N; Dalidowicz, M; Miller, L. What is the transmissibility and epidemiology of COVID-19 in children and adolescents? 2020 Aug 14; Document no.: EOC070201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST rapid review report)
Review History
EOC070201 RR: July 22, 2020
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC070201v2-01 ESR
Question Submitted
July 2, 2020
Date Completed
August 7, 2020
Status
5. Updated review
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC070201v2-01 ESR
Question Submitted
July 2, 2020
Date Completed
August 7, 2020
Status
5. Updated review
Research Team
EOC
Category
Infection Prevention and Control
Epidemiology
Subject
Pediatrics
Transmission
Symptoms
Natural History
Priority Level
Level 5 completed within 2 weeks
Cite As
Dalidowicz, M; Ellsworth, C. What is the transmissibility and epidemiology of COVID-19 in children and adolescents? 2020 Aug 7; Document no.: EOC070201v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 29 p. (CEST evidence search report)
Review History
EOC070201 RR: July 22, 2020
Related Documents
Documents

EOC070201v2-01 ESR

Read PDF Download PDF
Less detail
Document Type
Evidence Search Report
Review Code
EOC072102-01 ESR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC072102-01 ESR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Category
Epidemiology
Subject
Pediatrics
Natural History
Symptoms
Transmission
Population
All Pediatrics
Priority Level
Level 5 completed within 2 weeks
Cite As
Dalidowicz, M; Howell-Spooner, B; Ellsworth, C. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 31; Document no.: EOC072102-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 44 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Children and adolescents (0 to 18 years) contributed 1- 10% of laboratory confirmed cases of COVID-19 globally. · Children have been reported to have milder symptoms of COVID-19 and have shown better prognosis as compared to adults. · Severe cases presenting as a multisystem inflammatory syndrome in children (MIS-C) has been reported in some pediatric cases of COVID-19. Many of these children meet the criteria for complete or incomplete Kawasaki disease, but different clinical presentations of this inflammatory disorder are being reported. · Underlying medical conditions and comorbidities such as such as sickle cell disease, immunocompromised condition, obesity, cancer, cardiovascular disease, and asthma have been associated with severity and complications from COVID-19 infection in pediatric patients. · Although rare, death from COVID-19 in children have been reported, with a case fatality rate of less than 0.5%.
Category
Epidemiology
Subject
Pediatrics
Natural History
Symptoms
Transmission
Population
All Pediatrics
Priority Level
Level 5 completed within 2 weeks
Cite As
Asamoah, G; Muhajarine, N; Dalidowicz, M; Ellsworth, C; Howell-Spooner, B. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 27; Document no.: EOC072102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report)
Related Documents
Documents
Less detail

6 records – page 1 of 1.